SynthesisFrontiers in endocrinology2024
Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.
Synthesis in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Timing of parathyroidectomy in kidney transplant candidates: a systematic review and a proposed clinical algorithm.Frontiers in endocrinology · 2026Pooled it
- Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.Journal of clinical medicine · 2026Article
- Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease.Nutrients · 2026Review
- Prevalence and determinants of secondary hyperparathyroidism: IMOS-2021.Scientific reports · 2026Article
- Investigation of secondary hyperparathyroidism and its contributing factors in hemodialysis patients: A cross-sectional study.Journal of education and health promotion · 2026Article
- 4D CT-guided parathyroidectomy: improving operative efficiency in end-stage renal disease patients with medically refractory secondary hyperparathyroidism.International journal of surgery (London, England) · 2026Article
- Tubular functional capacity and maladaptive parathyroid hormone response in early-stage chronic kidney disease.Biomolecules & biomedicine · 2025Article
- Correlation between parathyroid volume and calcium and phosphorus metabolism in maintenance hemodialysis patients based on Doppler ultrasound technology.International urology and nephrology · 2025Article
- Hungry Bone Syndrome After Parathyroidectomy for Secondary Hyperparathyroidism: Pathogenesis and Contemporary Clinical Considerations.Journal of clinical medicine · 2025Review
- Essentials for parathyroid imaging and intervention: what radiologists need to know.Ultrasonography (Seoul, Korea) · 2025Article
- Article
- Whole Exome Sequencing in 26 Saudi Patients Expands the Mutational and Clinical Spectrum of Diabetic Nephropathy.Medicina (Kaunas, Lithuania) · 2025Article
- Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study.Frontiers in pharmacology · 2025Article
- Assessment of hyperparathyroidism secondary to CKD beyond laboratory tests: the important validation of the Parathyroid Assessment of Symptom (PAS) questionnaire for Portuguese language (Brazil).Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD. Methods: Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation. Results: Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20-68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35-88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74-88.00). Conclusions: SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.